Titre :

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Auteur(s) :

Robin, Marie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
De Wreede, Liesbeth C. [Auteur]
Wolschke, Christine [Auteur]
Schetelig, Johannes [Auteur]
Eikema, Diderik-Jan [Auteur]
Van Lint, Maria Teresa [Auteur]
Knelange, Nina [Auteur]
Beelen, Dietrich [Auteur]
Brecht, Arne [Auteur]
Niederwieser, Dietger [Auteur]
Vitek, Antonin [Auteur]
Bethge, Wolfgang [Auteur]
Arnold, Renate [Auteur]
Finke, Jurgen [Auteur]
Volin, Liisa [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Nagler, Arnon [Auteur]
Poire, Xavier [Auteur]
Einsele, Hermann [Auteur]
Chevallier, Patrice [Auteur]
Holler, Ernst [Auteur]
Ljungman, Per [Auteur]
Robinson, Stephen [Auteur]
Radujkovic, Aleksandar [Auteur]
Mclornan, Donal [Auteur]
Chalandon, Yves [Auteur]
Kroger, Nicolaus [Auteur]

Titre de la revue :

Haematologica

Nom court de la revue :

Haematologica

Numéro :

104

Date de publication :

2019-09-01

ISSN :

1592-8721

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year ...
Lire la suite >Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged ≥65 years. The main cause of death was relapse of the primary disease. Graft-versusLire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-30T10:26:56Z
2024-01-30T16:03:23Z